Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 639-646

  Hara, Tomoya ^a   Fukuda, Daiju ^a   Tanaka, Kimie ^b   Higashikuni, Yasutomi ^b   Hirata, Yoichiro ^c   Nishimoto, Sachiko ^a   Yagi, Shusuke ^a   Yamada, Hirotsugu ^a   Soeki, Takeshi ^a   Wakatsuki, Tetsuzo ^a   Shimabukuro, Michio ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Activated factor X; Atherosclerosis; Coagulation; Inflammation; Macrophages; Rivaroxaban

Indexed keywords

INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; RIVAROXABAN; TUMOR NECROSIS FACTOR ALPHA; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10A INHIBITOR; FACTOR X RECEPTORS; FIBRINOGEN RECEPTOR; GELATINASE B; MESSENGER RNA; MMP9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DISEASE COURSE; IN VITRO STUDY; LIPID STORAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; C57BL MOUSE; CELL LINE; CHEMISTRY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; THORACIC AORTA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; AORTA; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL LINE; DISEASE PROGRESSION; FACTOR XA INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; RIVAROXABAN; RNA, MESSENGER;

EID: 84941742835     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.023     Document Type: Article

References (43)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
3. Paoletti R., Gotto A.M., Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 2004, 109:III20-III26.
4. Borissoff J.I., Spronk H.M., ten Cate H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 2011, 364:1746-1760.
5. Croce K., Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol. 2007, 14:55-61.
6. Major C.D., Santulli R.J., Derian C.K., et al. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:931-939.
7. Gabazza E.C., Taguchi O., Kamada H., et al. Progress in the understanding of protease-activated receptors. Int. J. Hematol. 2004, 79:117-122.
8. Borensztajn K., Peppelenbosch M.P., Spek C.A. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol. Med. 2008, 14:429-440.
9. Rothmeier A.S., Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin. Immunopathol. 2012, 34:133-149.
10. Spronk H.M., de Jong A.M., Crijns H.J., et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014, 101:344-351.
11. Badeanlou L., Furlan-Freguia C., Yang G., et al. Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. Nat. Med. 2011, 17:1490-1497.
12. Ragosta M., Gimple L.W., Gertz S.D., et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994, 89:1262-1271.
13. Perzborn E., Strassburger J., Wilmen A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 2005, 3:514-521.
14. Roehrig S., Straub A., Pohlmann J., et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 2005, 48:5900-5908.
15. Perzborn E., Roehrig S., Straub A., et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 2011, 10:61-75.
16. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
17. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012, 366:9-19.
18. Mega J.L., Braunwald E., Wiviott S.D., et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am. J. Cardiol. 2013, 112:472-478.
19. Moghadasian M.H., Nguyen L.B., Shefer S., et al. Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols. Lab. Invest 1999, 79:355-364.
20. Nakashima Y., Plump A.S., Raines E.W., et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 1994, 14:133-140.
21. O'Neill T.P. Apolipoprotein E-deficient mouse model of human atherosclerosis. Toxicol. Pathol. 1997, 25:20-21.
22. -/-Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E496-E505.
23. Altman D.G. Comparing groups - continuous data. Practical Statistics for Medical Research 1991, 179-223. Chapman & HALL/CRC.
24. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 1955, 50:1096-1121.
25. Gulseth M.P., Michaud J., Nutescu E.A. Rivaroxaban: an oral direct inhibitor of factor Xa. Am. J. Health Syst. Pharm. 2008, 65:1520-1529.
26. Ellinghaus P., Laux V., Perzborn E. Effect of rivaroxaban on thrombin-induced pro-inflammatory gene expression in human umbilical vein endothelial cells. J. Thromb. Haemost. 2011, 9:1.
27. Tiwari R.L., Singh V., Barthwal M.K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med. Res. Rev. 2008, 28:483-544.
28. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365:883-891.
29. Ageno W., Spyropoulos A.C., Turpie A.G. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thromb. Haemost. 2012, 107:1027-1034.
30. Krantz M.J., Kaul S. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-Thrombolysis in myocardial infarction 51). J. Am. Coll. Cardiol. 2013, 62:777-781.
31. Santos-Gallego C.G., Badimon L., Badimón J.J. Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur. Heart J. Suppl. 2014, 16:A56-A60.
32. Heran C., Morgan S., Kasiewski C., et al. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur. J. Pharmacol. 2000, 389:201-207.
33. Schumacher W.A., Balasubramanian N., St Laurent D.R., et al. Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. Eur. J. Pharmacol. 1994, 259:165-171.
34. Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1238-1247.
35. Zhou Q., Bea F., Preusch M., et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediat. Inflamm. 2011, 2011:432080.
36. Borissoff J.I., Heeneman S., Kilinc E., et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010, 122:821-830.
37. Hezi-Yamit A., Wong P.W., Bien-Ly N., et al. Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades. Proc. Natl. Acad. Sci. USA. 2005, 102:12077-12082.
38. Nystedt S., Ramakrishnan V., Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J. Biol. Chem. 1996, 271:14910-14915.
39. Sparkenbaugh E.M., Chantrathammachart P., Mickelson J., et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014, 123:1747-1756.
40. Berkner K.L., Runge K.W. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J. Thromb. Haemost. 2004, 2:2118-2132.
41. Schurgers L.J., Joosen I.A., Laufer E.M., et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012, 7. e43229.
42. Furugohri T., Isobe K., Honda Y., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 2008, 6:1542-1549.
43. Pinto D.J., Orwat M.J., Koch S., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 2007, 50:5339-5356.